Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and Childhood Cancer Survivors' Quality of Life.
Differential effects of GVHD therapies on intestinal epithelium.
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity
Clinical Management of Acute Graft-Versus-Host Disease: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM
Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant
Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group
Prediction and Prognostication of Acute Graft-Versus-Host Disease by MAGIC Biomarkers.
Hematopoietic cell transplant compared with standard care in adolescents and young adults with sickle cell disease.
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD
Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group.
Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD.
Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC.
The Phase 2 Stargaze Trial of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Combination with Ruxolitinib for Steroid-Refractory Gastrointestinal (GI) Acute Graft-Versus-Host Disease (aGvHD): Comparisons with a MAGIC Control Cohort
The MAGIC composite response: a novel end point integrating clinical and biomarker parameters for acute GVHD.
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity
AML biology matters, so should we transplant ASAP?
Soluble urokinase plasminogen activator receptor and acute kidney injury in hematopoietic cell transplantation.
Correction: Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002.
Grade I acute graft-vs-host disease: Treat or not?
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD.
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis.
Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
A Day 14 Endpoint for Acute GVHD Clinical Trials
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD.
SoCS: Collaborative Research: Conversational Dynamics in Online Support Groups
Understanding the Effects of Self-Affirmation
DHB: Collaborative Research: Solving Critical Problems in Online Groups
International Conference on Social Influence to be held at the University of Valencia, Spain, June 16-18, 1990
Socialization in Small Groups: Assimilation and Accomodation
Group Socialization: Temporal Changes in Individual-Group Relations
Reaction to Attitudinal Deviance